Immune checkpoint blockade has become a paradigm-shifting treatment modality to combat cancer, while conventional administration of immune checkpoint inhibitors, such as anti-PD-L1 antibody (α-PD-L1), often shows uns...
详细信息
Immune checkpoint blockade has become a paradigm-shifting treatment modality to combat cancer, while conventional administration of immune checkpoint inhibitors, such as anti-PD-L1 antibody (α-PD-L1), often shows unsatisfactory immune responses and lead to severe immune-related adverse effects (irAEs). Herein, we develop a PD-L1 aptamer-based spherical nucleic acids (SNAs), which consists of oxaliplatin (OXA) encapsulated in a metal–organic framework nanoparticle core and a dense shell of aptPD-L1 (denoted as M@O-A). Upon light irradiation, this nanosystem enables concurrent photodynamic therapy (PDT), chemotherapy, and enhanced immunotherapy in one shot to inhibit both primary colorectal tumors and untreated distant tumors in mice. Notably, M@O-A shows scarcely any systemic immunotoxicity in a clinical irAEs-mimic transgenic mouse model. Collectively, this study presents a novel strategy for priming robust photo-immunotherapy against cancer with enhanced safety.
This study presents a novel intraoperative in vivo imaging approach which harnessed Cerenkov luminescence (CL) to detect primary and metastatic colorectal cancer (CRC) using clinically approved radiopharmaceuticals. I...
This study presents a novel intraoperative in vivo imaging approach which harnessed Cerenkov luminescence (CL) to detect primary and metastatic colorectal cancer (CRC) using clinically approved radiopharmaceuticals. In the mice and swine experiments, the proposed approach effectively improved the effect of CRC surgery. The approach is believed to be promising for utilizing CL in open surgery. Further details can be found in the article by Zeyu Zhang, Yawei Qu, Yu Cao et al. ( e201960152 )
暂无评论